Stockreport

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial [Yahoo! Finance]

Cardiff Oncology, Inc.  (CRDF) 
PDF - In the experimental arms, 30mg dose of onvansertib demonstrated a higher ORR compared to 20mg dose of onvansertib (64% vs. 50%) with deeper tumor regression in the 30 [Read more]